Abstract

Public Health Relevance

Respiratory syncytial virus (RSV) is the most important pathogen for lower respiratory tract infection in infants, but there are no approved vaccines. RSV live attenuated vaccines (LAV) are the most clinically advanced candidates but have two main problems, lack of potency and genetic instability. This study will compare two novel RSV LAVs with improved potency and stability in relevant pre-clinical models, in preparation for taking a lead candidate to clinical trial.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
5R44AI134267-03
Application #
9631419
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Kim, Sonnie
Project Start
2017-07-01
Project End
2019-07-31
Budget Start
2019-02-01
Budget End
2019-07-31
Support Year
3
Fiscal Year
2019
Total Cost
Indirect Cost

  Institution

Name
Meissa Vaccines, Inc.
Department
Type
DUNS #
079471427
City
South San Francisco
State
CA
Country
United States
Zip Code
94080